OS Therapies Incorporated (OSTX:NYSEMKT) closed at $1.41 on October 15, 2026, up 1.44% on the day. The stock trades 37.3% below its 52-week high of $2.25 and 22.6% above its 52-week low of $1.15. Over the past year, it lost 28.7%. OS Therapies Incorporated is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -10.90% | -21.91% | -9.15% | +0.72% | -28.72% |
In 252 trading sessions since October 14, 2025, OSTX closed higher on 113 days (45%). Its best day was April 24, 2026 (+22.07%) and its worst was June 30, 2026 (-15.18%). The stock moved 10% or more in a single session 8 times.
OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OS Therapies was launched to meet significant unmet need for new treatments in cancers of the bone in kids and adults. Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. At OST, we are trying to answer the calls for new treatments, considering there have been no new treatments for OS in over 30 years. OST has expanded the pipeline beyond Osteosarcoma with OST-HER2 into other solid tumors with the same recurrence mechanism of action, including Breast, Esophageal and Lung cancer. With the addition of OST-tADC, considered a next generation Antibody Drug Conjugate (ADC) platform technology, we will be targeting Ovarian, Lung and Pancreatic cancer.
Find more stocks like OSTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.